Evidence map›Paper›PMID 41793151›Full record

Trial reportFuture oncology (London, England)2026

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.

Pankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew Kuykendall, Francesca Palandri, John Mascarenhas, Haifa Al-Ali and 4 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pankit VachhaniDivision of Hematology / Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Abdulraheem YacoubDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Raajit RampalDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Terrence BradleyDivision of Hematology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.
Claire HarrisonHematology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
Tania JainHematology Oncology, Johns Hopkins University, Baltimore, MD, USA.
Andrew KuykendallHematology / Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Francesca PalandriIRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
John MascarenhasTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Haifa Al-AliHematology Oncology, University Hospital of Halle, Halle, Germany.
Francesco PassamontiDipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milan, Italy.
Wayne RothbaumKartos Therapeutics, Inc., Redwood City, CA, USA.
Srdan VerstovsekKartos Therapeutics, Inc., Redwood City, CA, USA.
Florian H HeidelHematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Most myelofibrosis (MF) patients treated with ruxolitinib fail to achieve optimal response (i.e., spleen volume reduction  ≥35% [SVR35] and improvement in total symptom score ≥50% [TSS50], and instead experience suboptimal reductions in spleen volume and constitutional symptoms. Maximizing SVR and TSS is critical for MF patients, as both are associated with improved quality of life (QoL) and overall survival (OS). Navtemadlin is a potent, selective, oral MDM2 inhibitor that restores p53 activity, inducing apoptosis of malignant

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBenzamidesJanus Kinase InhibitorsPrimary MyelofibrosisPyrazolesAgedBridged-Ring CompoundsDouble-Blind MethodFemaleHumansMaleMiddle AgedNitrilesProto-Oncogene Proteins c-mdm2PyrimidinesQuality of LifeBenzamidesBridged-Ring CompoundsJanus Kinase InhibitorsNitrilespacritinibProto-Oncogene Proteins c-mdm2PyrazolesPyrimidinesruxolitinibTumor Suppressor Protein p53JAK inhibitor-naïveMDM2 inhibitorMyelofibrosisnavtemadlinp53phase III POIESIS trialspleen volume reductionsuboptimal response

Identifiers

PMID41793151
PMCPMC12980654

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.